Placebo — Inactive substance used in clinical trials

A placebo is an intervention with no therapeutic effect, commonly referred to as a "dummy" or sham treatment. In cancer research, placebos are most frequently formulated as inert tablets, capsules, or saline infusions identical in appearance to the investigational therapy. They serve as an essential experimental control to account for psychological expectations, the natural fluctuation of disease symptoms, and observer bias.

In oncology, ethics dictate that participants are never deprived of life-extending or standard therapies. Consequently, placebos are typically paired with the current standard of care—for example, comparing standard chemotherapy plus a new targeted drug against standard chemotherapy plus a placebo. This rigorous design ensures that any observed benefits or adverse events can be definitively attributed to the investigational agent.

For someone considering a clinical trial, understanding the role of a placebo provides reassurance about personal safety and treatment standards. Many patients worry they will receive "no treatment" if enrolled in a study. Knowing that placebos in cancer trials are almost always combined with standard therapeutic regimens helps alleviate fear and supports informed decision-making. Informed consent documents explicitly state whether a trial includes a placebo, what the chances of receiving it are, and how side effects or disease progression will be monitored. This clarity empowers patients to evaluate research opportunities objectively.

A placebo is not a biological marker, so there are no diagnostic tests for it. Instead, clinical trials evaluate how patients receiving a placebo respond compared to those receiving the experimental drug. Trial protocols monitor standardised clinical biomarkers, including tumour size via computed tomography (CT) scans, circulating tumour markers, and complete blood counts. By comparing laboratory trends and imaging outcomes between the active and placebo arms, investigators measure progression-free survival, overall survival, and treatment-related toxicities in an unbiased manner.

Placebos are used in clinical trials across virtually all cancer types, particularly in phase III randomised controlled trials. Common settings include advanced breast cancer, non-small cell lung cancer, colorectal cancer, prostate cancer, and haematological malignancies like leukaemia or lymphoma. In each of these malignancies, placebos are introduced when testing add-on therapies—such as combining novel immunotherapies or targeted kinase inhibitors with standard systemic chemotherapy or hormonal agents to establish whether the new agent confers survival or response benefits.

The use of a placebo directly guides whether a new drug gains regulatory approval to become a new standard treatment. If a study demonstrates that adding an experimental drug outperforms adding a placebo to baseline therapy, clinical guidelines change globally. For individual patients, protocol rules outline when "unblinding" occurs—identifying whether a person received the placebo or active drug—often allowing those on the placebo arm to cross over to the active treatment if their cancer progresses.